MX2009013926A - Compuestos de etinilindol. - Google Patents
Compuestos de etinilindol.Info
- Publication number
- MX2009013926A MX2009013926A MX2009013926A MX2009013926A MX2009013926A MX 2009013926 A MX2009013926 A MX 2009013926A MX 2009013926 A MX2009013926 A MX 2009013926A MX 2009013926 A MX2009013926 A MX 2009013926A MX 2009013926 A MX2009013926 A MX 2009013926A
- Authority
- MX
- Mexico
- Prior art keywords
- cyslt
- chronic
- sinusitis
- syndrome
- oral
- Prior art date
Links
- VYWBXQOYASJNLB-UHFFFAOYSA-N 2-ethynyl-1h-indole Chemical class C1=CC=C2NC(C#C)=CC2=C1 VYWBXQOYASJNLB-UHFFFAOYSA-N 0.000 title 1
- 206010011224 Cough Diseases 0.000 abstract 2
- 102000004155 Cysteinyl leukotriene receptor 2 Human genes 0.000 abstract 2
- 108090000655 Cysteinyl leukotriene receptor 2 Proteins 0.000 abstract 2
- 102000010918 Cysteinyl leukotriene receptors Human genes 0.000 abstract 2
- 108050001116 Cysteinyl leukotriene receptors Proteins 0.000 abstract 2
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 abstract 2
- 230000003042 antagnostic effect Effects 0.000 abstract 2
- 208000006673 asthma Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000005923 long-lasting effect Effects 0.000 abstract 2
- 230000003389 potentiating effect Effects 0.000 abstract 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 abstract 1
- 206010001076 Acute sinusitis Diseases 0.000 abstract 1
- 206010006458 Bronchitis chronic Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 206010009137 Chronic sinusitis Diseases 0.000 abstract 1
- 206010014561 Emphysema Diseases 0.000 abstract 1
- 208000029523 Interstitial Lung disease Diseases 0.000 abstract 1
- 206010035664 Pneumonia Diseases 0.000 abstract 1
- 206010039085 Rhinitis allergic Diseases 0.000 abstract 1
- 201000010105 allergic rhinitis Diseases 0.000 abstract 1
- 206010006451 bronchitis Diseases 0.000 abstract 1
- 208000007451 chronic bronchitis Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 208000027157 chronic rhinosinusitis Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 abstract 1
- 208000005069 pulmonary fibrosis Diseases 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 201000009890 sinusitis Diseases 0.000 abstract 1
- 201000002859 sleep apnea Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008325815 | 2008-12-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009013926A true MX2009013926A (es) | 2010-06-22 |
Family
ID=42110130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009013926A MX2009013926A (es) | 2008-12-22 | 2009-12-17 | Compuestos de etinilindol. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8115014B2 (enExample) |
| EP (1) | EP2206698B1 (enExample) |
| JP (2) | JP5012884B2 (enExample) |
| KR (1) | KR101464778B1 (enExample) |
| CN (1) | CN101759628B (enExample) |
| AU (1) | AU2009250960C1 (enExample) |
| BR (1) | BRPI0905601A2 (enExample) |
| CA (1) | CA2688614C (enExample) |
| DK (1) | DK2206698T3 (enExample) |
| ES (1) | ES2387185T3 (enExample) |
| IL (1) | IL202869A (enExample) |
| MX (1) | MX2009013926A (enExample) |
| NZ (1) | NZ582208A (enExample) |
| PL (1) | PL2206698T3 (enExample) |
| PT (1) | PT2206698E (enExample) |
| RU (1) | RU2505531C2 (enExample) |
| TW (1) | TWI469965B (enExample) |
| ZA (1) | ZA200909096B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5257490B2 (ja) | 2010-06-21 | 2013-08-07 | 小野薬品工業株式会社 | ４，４’−［４−フルオロ−７−（｛４−［４−（３−フルオロ−２−メチルフェニル）ブトキシ］フェニル｝エチニル）−２−メチル−１ｈ−インドール−１，３−ジイル］ジブタン酸、４，４’−［２−メチル−７−（｛４−［４−（ペンタフルオロフェニル）ブトキシ］フェニル｝エチニル）−１ｈ−インドール−１，３−ジイル］ジブタン酸および４，４’−［４−フルオロ−２−メチル−７−（｛４−［４−（２，３，４，６−テトラフルオロフェニル）ブトキシ］フェニル｝エチニル）−１ｈ−インドール−１，３−ジイル］ジブタン酸の新規結晶形 |
| KR101171790B1 (ko) | 2010-07-30 | 2012-08-13 | 현대자동차주식회사 | 인출식 자전거 캐리어 |
| WO2012089633A1 (fr) | 2010-12-28 | 2012-07-05 | Sanofi | Nouveaux derives de pyrimidines, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb) |
| EP2537866A1 (en) * | 2011-06-21 | 2012-12-26 | Serumwerk Bernburg AG | Hydroxyethyl starch derivatives, method for manufacturing the same and therapeutical uses thereof |
| CN103893146A (zh) * | 2012-12-25 | 2014-07-02 | 天津药物研究院 | 含福多司坦缓释剂型 |
| US11427591B2 (en) * | 2018-10-17 | 2022-08-30 | Insilico Medicine Ip Limited | Kinase inhibitors |
| US20230147364A1 (en) * | 2020-04-30 | 2023-05-11 | Kyoto University | Prophylactic or therapeutic agent for rna virus-related diseases |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE555319A (enExample) | 1956-03-21 | 1900-01-01 | ||
| US3095355A (en) | 1961-10-12 | 1963-06-25 | Revlon | Aerosol composition |
| JPH01192476A (ja) | 1988-01-25 | 1989-08-02 | Kawasaki Steel Corp | 溶接鋼管の製造方法 |
| US5137910A (en) * | 1989-05-05 | 1992-08-11 | C.D. Searle & Co. | Compositions containing indole-2-carboxylate compounds for treatment of CNS disorders |
| US5229413A (en) * | 1989-05-05 | 1993-07-20 | G. D. Searle & Co. | Compositions containing indole-2-carboxylate compounds for treatment of CNS disorders |
| JPH0347123A (ja) | 1989-05-05 | 1991-02-28 | G D Searle & Co | インドール―２―カルボキシレート化合物類を含有するｃｎｓ疾患治療用組成物 |
| CA2019335C (en) | 1989-06-27 | 2000-08-01 | Mitoshi Konno | Phenylalkan (en)oic acids |
| GB9027018D0 (en) * | 1990-12-12 | 1991-01-30 | Ici Plc | Heterocyclic compounds |
| EP0648208A1 (en) * | 1993-04-05 | 1995-04-19 | Fujisawa Pharmaceutical Co., Ltd. | Indole derivatives as testosterone 5 alpha-reductase inhibitors |
| JP3020612B2 (ja) | 1995-10-10 | 2000-03-15 | ファイザー インク． | ロイコトリエンアンタゴニストとしてのインドールカルバメート類 |
| FR2766824B1 (fr) * | 1997-07-30 | 1999-09-10 | Adir | Nouveaux composes heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| GB9902455D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
| AU2001270200A1 (en) | 2000-06-27 | 2002-01-08 | Smith Kline Beecham Corporation | Fatty acid synthase inhibitors |
| JP2003025362A (ja) | 2001-07-18 | 2003-01-29 | Nippon Tokushu Toryo Co Ltd | 通気性を有する発泡プラスチック及びその製法 |
| US6867224B2 (en) | 2002-03-07 | 2005-03-15 | Warner-Lambert Company | Compounds that modulate PPAR activity and methods of preparation |
| EP1515716A2 (en) | 2002-04-03 | 2005-03-23 | Astrazeneca AB | Indole derivatives having anti-angiogenetic activity |
| DE60313769T2 (de) | 2002-04-23 | 2008-03-06 | Aventis Pharmaceuticals Inc. | 3-(pyridinyl-amino)-1h-indol-2-carbonsäure-verbindungen als inhibitoren der interleukin-4 genexpression |
| SE0202241D0 (sv) | 2002-07-17 | 2002-07-17 | Astrazeneca Ab | Novel Compounds |
| EP1628970A2 (en) | 2003-04-30 | 2006-03-01 | The Institutes of Pharmaceutical Discovery, LLC | Heterocycle substituted carboxylic acids as inhibitors of protein tyrosine phosphatase-1b |
| CA2537355C (en) | 2003-09-01 | 2012-10-09 | Ono Pharmaceutical Co., Ltd. | Condensed ring compound and use thereof |
| KR101377790B1 (ko) * | 2005-02-25 | 2014-03-27 | 오노 야꾸힝 고교 가부시키가이샤 | 인돌 화합물 및 이의 용도 |
-
2009
- 2009-12-10 TW TW98142268A patent/TWI469965B/zh not_active IP Right Cessation
- 2009-12-15 CA CA2688614A patent/CA2688614C/en not_active Expired - Fee Related
- 2009-12-15 AU AU2009250960A patent/AU2009250960C1/en not_active Ceased
- 2009-12-17 MX MX2009013926A patent/MX2009013926A/es active IP Right Grant
- 2009-12-21 RU RU2009147506/04A patent/RU2505531C2/ru not_active IP Right Cessation
- 2009-12-21 EP EP09180244A patent/EP2206698B1/en not_active Not-in-force
- 2009-12-21 NZ NZ582208A patent/NZ582208A/en not_active IP Right Cessation
- 2009-12-21 ZA ZA200909096A patent/ZA200909096B/en unknown
- 2009-12-21 BR BRPI0905601-7A patent/BRPI0905601A2/pt not_active IP Right Cessation
- 2009-12-21 CN CN2009102608650A patent/CN101759628B/zh not_active Expired - Fee Related
- 2009-12-21 PL PL09180244T patent/PL2206698T3/pl unknown
- 2009-12-21 IL IL202869A patent/IL202869A/en not_active IP Right Cessation
- 2009-12-21 PT PT09180244T patent/PT2206698E/pt unknown
- 2009-12-21 JP JP2009289494A patent/JP5012884B2/ja active Active
- 2009-12-21 KR KR1020090128213A patent/KR101464778B1/ko not_active Expired - Fee Related
- 2009-12-21 DK DK09180244.7T patent/DK2206698T3/da active
- 2009-12-21 ES ES09180244T patent/ES2387185T3/es active Active
- 2009-12-22 US US12/644,378 patent/US8115014B2/en not_active Expired - Fee Related
-
2012
- 2012-03-07 JP JP2012050217A patent/JP2012144546A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP2206698B1 (en) | 2012-07-18 |
| KR20100074036A (ko) | 2010-07-01 |
| BRPI0905601A2 (pt) | 2012-05-02 |
| TWI469965B (zh) | 2015-01-21 |
| EP2206698A1 (en) | 2010-07-14 |
| AU2009250960C1 (en) | 2014-01-23 |
| NZ582208A (en) | 2011-05-27 |
| JP2012144546A (ja) | 2012-08-02 |
| CN101759628A (zh) | 2010-06-30 |
| RU2505531C2 (ru) | 2014-01-27 |
| RU2009147506A (ru) | 2011-06-27 |
| IL202869A (en) | 2015-02-26 |
| ES2387185T3 (es) | 2012-09-17 |
| JP5012884B2 (ja) | 2012-08-29 |
| US8115014B2 (en) | 2012-02-14 |
| CA2688614C (en) | 2015-01-06 |
| DK2206698T3 (da) | 2012-08-27 |
| PL2206698T3 (pl) | 2012-12-31 |
| ZA200909096B (en) | 2010-09-29 |
| KR101464778B1 (ko) | 2014-11-24 |
| US20100160647A1 (en) | 2010-06-24 |
| AU2009250960B2 (en) | 2013-09-05 |
| CA2688614A1 (en) | 2010-06-22 |
| TW201026664A (en) | 2010-07-16 |
| CN101759628B (zh) | 2013-02-27 |
| AU2009250960A1 (en) | 2010-07-08 |
| PT2206698E (pt) | 2012-08-03 |
| JP2010168359A (ja) | 2010-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009013926A (es) | Compuestos de etinilindol. | |
| MX2009009443A (es) | Compuestos de pirimidina hidrazida como inhibidores de pgds. | |
| TNSN08104A1 (en) | Pyrimidine amide compounds as pgds inhibitors | |
| NZ709197A (en) | 3,5-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds | |
| MD20140008A2 (ro) | 3,5-Diamino-6-cloro-N-(N-(4-(4-(2-(hexil (2,3,4,5,6-pentahidroxihexil) amino) etoxi) fenil) butil) carbamimidoil)pirazină-2-carboxamidă | |
| BR0107934A (pt) | Carboxamidas de pirimidina úteis como inibidores de isozimas pde4 | |
| WO2008063581A3 (en) | Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs | |
| NO20074670L (no) | Indolforbindelser og anvendelse derav | |
| WO2006117299A3 (en) | Novel crystalline forms of tiotropium bromide | |
| NZ590774A (en) | Substantially pure 5R enantiomers of pioglitazone and rosiglitazone for treating inflammatory respiratory diseases | |
| WO2006117300A3 (en) | Crystalline forms of tiotropium bromide | |
| MY159172A (en) | Inhalable particles comprising tiotropium | |
| NO20075287L (no) | Kombinasjon av antikolinergika og leukotnen-reseptorantagonister for behandling av andedrettslidelser | |
| NZ599099A (en) | Phenyloxadiazole derivatives as pgds inhibitors | |
| MX2009003100A (es) | Inhibidores de fosfodiesterasa tipo iv. | |
| NZ589293A (en) | Antiallergic marine biopolymers comprising iota-carrageenan | |
| JP2013538857A5 (enExample) | ||
| TW200616967A (en) | Novel indazole carboxamides and their use | |
| NZ709199A (en) | Arylalkyl-and aryloxyalkyl-substituted epithelial sodium channel blocking compounds | |
| NO20081483L (no) | Kombinasjon av forbindelser som kan brukes ved behandling av respiratoriske sykdommer, spesielt kronisk obstruktiv pulmonaer sykdom (COPD) og astma | |
| UA115989C2 (uk) | Фармацевтична композиція для інгалятора сухого порошку, що містить антагоністи мускаринових рецепторів тривалої дії | |
| WO2007005534A3 (en) | Chemical compounds | |
| MX2010008685A (es) | Farmacoforos duales-antagonistas muscarinicos de pde4. | |
| WO2008048560A3 (en) | Toll-like receptor agonist regulation of vegf-induced tissue responses | |
| WO2006129158A3 (en) | 3 - indazolyl - isoxazoline derivatives as inhibitors of phosphodiesterase type - i |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |